Division of Endocrinology, University of Miami, Miami, Florida, USA.
Diabetes Care. 2010 Mar;33(3):620-5. doi: 10.2337/dc09-1770. Epub 2009 Dec 23.
OBJECTIVE We studied the C-peptide response to oral glucose with progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. RESEARCH DESIGN AND METHODS Among 504 DPT-1 participants <15 years of age, longitudinal analyses were performed in 36 progressors and 80 nonprogressors. Progressors had oral glucose tolerance tests (OGTTs) at baseline and every 6 months from 2.0 to 0.5 years before diagnosis; nonprogressors had OGTTs over similar intervals before their last visit. Sixty-six progressors and 192 nonprogressors were also studied proximal to and at diagnosis. RESULTS The 30-0 min C-peptide difference from OGTTs performed 2.0 years before diagnosis in progressors was lower than the 30-0 min C-peptide difference from OGTTs performed 2.0 years before the last visit in nonprogressors (P < 0.01) and remained lower over time. The 90-60 min C-peptide difference was positive at every OGTT before diagnosis in progressors, whereas it was negative at every OGTT before the last visit in nonprogressors (P < 0.01 at 2.0 years). The percentage whose peak C-peptide occurred at 120 min was higher in progressors at 2.0 years (P < 0.05); this persisted over time (P < 0.001 at 0.5 years). However, the peak C-peptide levels were only significantly lower at 0.5 years in progressors (P < 0.01). The timing of the peak C-peptide predicted type 1 diabetes (P < 0.001); peak C-peptide levels were less predictive (P < 0.05). CONCLUSIONS A decreased early C-peptide response to oral glucose and an increased later response occur at least 2 years before the diagnosis of type 1 diabetes.
我们研究了糖尿病预防试验-1(DPT-1)参与者中,从进展到 1 型糖尿病时的口服葡萄糖后 C 肽反应。
在 504 名年龄小于 15 岁的 DPT-1 参与者中,对 36 名进展者和 80 名非进展者进行了纵向分析。进展者在诊断前 2.0 年至 0.5 年的每 6 个月进行口服葡萄糖耐量试验(OGTT);而非进展者在最后一次就诊前的相似时间段内进行 OGTT。对 66 名进展者和 192 名非进展者在接近诊断和诊断时也进行了研究。
进展者在诊断前 2.0 年进行的 OGTT 中 30-0 分钟 C 肽差值低于非进展者在最后一次就诊前 2.0 年进行的 OGTT 中 30-0 分钟 C 肽差值(P < 0.01),且随着时间的推移差值持续降低。进展者在诊断前的每一次 OGTT 中,90-60 分钟 C 肽差值均为正值,而非进展者在最后一次就诊前的每一次 OGTT 中,90-60 分钟 C 肽差值均为负值(P < 0.01,在 2.0 年时)。在诊断前 2.0 年,进展者的峰值 C 肽出现在 120 分钟的百分比更高(P < 0.05);这一趋势随着时间的推移而持续(在 0.5 年时,P < 0.001)。然而,进展者仅在 0.5 年时的峰值 C 肽水平显著降低(P < 0.01)。峰值 C 肽出现的时间预测 1 型糖尿病(P < 0.001);而峰值 C 肽水平的预测作用较小(P < 0.05)。
在 1 型糖尿病诊断前至少 2 年,就会出现口服葡萄糖后 C 肽早期反应降低和后期反应增加的情况。